Benzinga Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally
Analysts launch bullish coverage on BillionToOne as its IPO surge, prenatal growth, and molecular diagnostics platform drive optimism. read more
Analysts launch bullish coverage on BillionToOne as its IPO surge, prenatal growth, and molecular diagnostics platform drive optimism. read more